Emergent BioSolutions, Inc. (EBS)
6.21
+0.11
(+1.80%)
USD |
NYSE |
Sep 01, 16:00
6.21
0.00 (0.00%)
After-Hours: 20:00
Emergent BioSolutions Research and Development Expense (Annual) : 53.80M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 53.80M |
| December 31, 2024 | 64.90M |
| December 31, 2023 | 107.80M |
| December 31, 2022 | 188.30M |
| December 31, 2021 | 235.20M |
| December 31, 2020 | 205.50M |
| December 31, 2019 | 226.20M |
| December 31, 2018 | 142.80M |
| December 31, 2017 | 97.40M |
| December 31, 2016 | 107.59M |
| December 31, 2015 | 109.36M |
| December 31, 2014 | 150.83M |
| Date | Value |
|---|---|
| December 31, 2013 | 119.93M |
| December 31, 2012 | 123.23M |
| December 31, 2011 | 124.83M |
| December 31, 2010 | 89.30M |
| December 31, 2009 | 74.59M |
| December 31, 2008 | 59.47M |
| December 31, 2007 | 53.96M |
| December 31, 2006 | 45.50M |
| December 31, 2005 | 18.38M |
| December 31, 2004 | 10.12M |
| December 31, 2003 | 6.327M |
| December 31, 2002 | 2.808M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Exelixis, Inc. | 825.00M |
| Capricor Therapeutics, Inc. | 83.50M |
| ADMA Biologics, Inc. | 4.762M |
| Akebia Therapeutics, Inc. | 61.09M |
| Arcutis Biotherapeutics, Inc. | 77.05M |